Wróć

Wybierz swój region

Corporate

Europa:

Flaga Albania Albania Flaga Bośnia i Hercegowina Bośnia i Hercegowina Flaga Bułgaria Bułgaria Flaga Chorwacja Chorwacja Flaga Cypr Cypr Flaga Czarnogóra Czarnogóra Flaga Czechy Czechy Flaga Dania Dania Flaga Estonia Estonia Flaga Hiszpania Hiszpania Flaga Kosowo Kosowo Flaga Litwa Litwa Flaga Łotwa Łotwa Flaga Luksemburg Luksemburg Flaga Macedonia Macedonia Flaga Niemcy Niemcy Flaga Polska Polska Flaga Portugalia Portugalia Flaga Rumunia Rumunia Flaga Serbia Serbia Flaga Słowacja Słowacja Flaga Słowenia Słowenia Flaga Szwajcaria Szwajcaria Flaga Szwecja Szwecja Flaga Turcja Turcja Flaga Węgry Węgry Flaga Wielka Brytania Wielka Brytania Flaga Włochy Włochy

Azja:

Flaga UAE UAE Flaga Hong Kong Hong Kong Flaga Kuwejt Kuwejt Flaga Liban Liban

Afryka:

Flaga RPA RPA

Umów konsultację o krwi pępowinowej

Umawiam

Skontaktuj się z nami już dziś!

Chcesz dowiedzieć się więcej o naszych usługach? Uzupełnij poniższy formularz, a my skontaktujemy się z Tobą jak najszybciej, aby udzielić Ci wszelkich potrzebnych informacji oraz odpowiedzieć na Twoje pytania.

    Uprzejmie informujemy, że dane osobowe podane w formularzu będą przetwarzane przez Polski Bank Komórek Macierzystych Sp. z o.o. („PBKM”) z siedzibą w Warszawie, Al. Jana Pawła II 29 w celu kontaktu telefonicznego w związku z udzieleniem informacji na temat usługi.

    Zestawienie leczonych pacjentów

    Terapie
    komórkami macierzystymi

    Terapie komórkami macierzystymi

    Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).

    Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.

    Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.

    Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.

    Data aktualizacji: 06.2026

    Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord

    Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
    Lp. Źródło Typ źródła Wskazanie Obszar medycyny Rok podania Terapia Kraj Wiek odbiorcy
    4001 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Poland 26
    4002 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Poland 56
    4003 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Poland 63
    4004 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Poland 61
    4005 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Poland 70
    4006 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Poland 66
    4007 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Germany 48
    4008 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Germany 58
    4009 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2021 Standard Therapy Germany 59
    4010 Apheresis Allogeneic Myelofibrosis Hematology 2021 Standard Therapy Poland 62
    4011 Apheresis Allogeneic Myelofibrosis Hematology 2021 Standard Therapy Poland 63
    4012 Apheresis Allogeneic Myelofibrosis Hematology 2021 Standard Therapy Poland 64
    4013 Apheresis Allogeneic Myelofibrosis Hematology 2021 Standard Therapy Poland 66
    4014 Apheresis Allogeneic Myelofibrosis Hematology 2021 Standard Therapy Poland 65
    4015 Apheresis Allogeneic Myelofibrosis Hematology 2021 Standard Therapy Poland 56
    4016 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2021 Standard Therapy Poland 75
    4017 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2021 Standard Therapy Poland 65
    4018 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2021 Standard Therapy Poland 51
    4019 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2021 Standard Therapy Poland 63
    4020 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2021 Standard Therapy Poland 75
    4021 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2021 Standard Therapy Poland 64
    4022 Apheresis Allogeneic Myeloma Multiplex Hematology 2021 Standard Therapy Poland 48
    4023 Apheresis Allogeneic Myeloma Multiplex Hematology 2021 Standard Therapy Poland 53
    4024 Apheresis Allogeneic Myeloproliferative Neoplasms Hematology 2021 Standard Therapy Poland 67
    4025 Apheresis Allogeneic Myeloproliferative Neoplasms Hematology 2021 Standard Therapy Poland 58
    4026 Apheresis Allogeneic Myeloproliferative Neoplasms Hematology 2021 Standard Therapy Germany 51
    4027 Apheresis Allogeneic No Data Hematology 2021 Standard Therapy Poland 64
    4028 Apheresis Allogeneic No Data Hematology 2021 Standard Therapy Poland 57
    4029 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 30
    4030 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 51
    4031 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 58
    4032 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 56
    4033 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 58
    4034 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 50
    4035 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 53
    4036 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 20
    4037 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 64
    4038 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Poland 66
    4039 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 62
    4040 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 61
    4041 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 49
    4042 Apheresis Allogeneic Non-Hodgkin-Lymphoma-Relapse Hematology 2021 Standard Therapy Germany 62
    4043 Apheresis Allogeneic Osteomyelitis Hematology 2021 Standard Therapy Poland 47
    4044 Apheresis Allogeneic Osteomyelofibrosis Hematology 2021 Standard Therapy Poland 69
    4045 Apheresis Allogeneic Osteomyelofibrosis Hematology 2021 Standard Therapy Poland 43
    4046 Apheresis Autologous Osteosclerotic Myeloma Hematology 2021 Standard Therapy Germany 54
    4047 Apheresis Allogeneic Other Myelodysplastic Syndromes Hematology 2021 Standard Therapy Poland 65
    4048 Apheresis Allogeneic Other Myelofibrosis Hematology 2021 Standard Therapy Poland 68
    4049 Apheresis Allogeneic Other Myelofibrosis Hematology 2021 Standard Therapy Poland 70
    4050 Apheresis Allogeneic Other Myelofibrosis Hematology 2021 Standard Therapy Poland 72
    4051 Apheresis Allogeneic Other Plasma Cell Disorder Hematology 2021 Standard Therapy Poland 67
    4052 Apheresis Allogeneic Peripheral T-Cell Lymphoma Hematology 2021 Standard Therapy Poland 45
    4053 Apheresis Allogeneic Philadelphia-Positive Acute Lymphoblastic Leukemia Hematology 2021 Standard Therapy Poland 61
    4054 Apheresis Allogeneic Polycythemia Vera Hematology 2021 Standard Therapy Poland 65
    4055 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 71
    4056 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 66
    4057 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 62
    4058 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 53
    4059 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 44
    4060 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 54
    4061 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 65
    4062 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 65
    4063 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2021 Standard Therapy Germany 60
    4064 Apheresis Allogeneic Primary Myelofibrosis Hematology 2021 Standard Therapy Poland 66
    4065 Apheresis Allogeneic Primary Myelofibrosis Hematology 2021 Standard Therapy Poland 63
    4066 Apheresis Allogeneic Primary Myelofibrosis Hematology 2021 Standard Therapy Poland 62
    4067 Apheresis Allogeneic Primary Myelofibrosis Hematology 2021 Standard Therapy Poland 64
    4068 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2021 Standard Therapy Poland 68
    4069 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2021 Standard Therapy Poland 64
    4070 Apheresis Allogeneic Refractory Cytopenia Hematology 2021 Standard Therapy Poland 6
    4071 Apheresis Allogeneic Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia Hematology 2021 Standard Therapy Poland 58
    4072 Apheresis Allogeneic Secondary Acute Myeloid Leukemia Hematology 2021 Standard Therapy Germany 70
    4073 Apheresis Allogeneic Secondary Acute Myeloid Leukemia Hematology 2021 Standard Therapy Germany 64
    4074 Apheresis Allogeneic Secondary Acute Myeloid Leukemia Hematology 2021 Standard Therapy Germany 39
    4075 Apheresis Allogeneic Secondary Acute Myeloid Leukemia Hematology 2021 Standard Therapy Germany 60
    4076 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2021 Standard Therapy Poland 35
    4077 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2021 Standard Therapy Poland 58
    4078 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2021 Standard Therapy Poland 41
    4079 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2021 Standard Therapy Poland 38
    4080 Apheresis Allogeneic Severe Combined Immunodeficiency Hematology 2021 Standard Therapy Poland 1
    4081 Apheresis Allogeneic Severe Combined Immunodeficiency Hematology 2021 Standard Therapy Poland 1
    4082 Apheresis Allogeneic T-Cell Lymphoblastic Lymphoma Hematology 2021 Standard Therapy Germany 26
    4083 Apheresis Allogeneic T-Cell Lymphoblastic Lymphoma Hematology 2021 Standard Therapy Germany 37
    4084 Apheresis Autologous T-Cell Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 54
    4085 Apheresis Autologous T-Cell Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 66
    4086 Apheresis Autologous T-Cell Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 66
    4087 Apheresis Autologous T-Cell Non-Hodgkin Lymphoma Hematology 2021 Standard Therapy Germany 29
    4088 Apheresis Allogeneic T-Cell-Lymphoma Hematology 2021 Standard Therapy Poland 45
    4089 Apheresis Autologous Testicular Cancer Hematology 2021 Standard Therapy Germany 33
    4090 Apheresis Allogeneic Β – Thalassemia Hematology 2021 Standard Therapy Poland 17
    4091 Adipose Tissue Autologous Gonarthrosis Orthopedy 2021 Experimental Therapy Poland 51
    4092 Adipose Tissue Autologous Gonarthrosis Orthopedy 2021 Experimental Therapy Poland 44
    4093 Adipose Tissue Autologous Gonarthrosis Orthopedy 2021 Experimental Therapy Poland 35
    4094 Adipose Tissue Autologous Internal Damage To The Knee Joint Orthopedy 2021 Experimental Therapy Poland 41
    4095 Adipose Tissue Autologous Soft Tissue Diseases Related To Use, Overload And Pressure Orthopedy 2021 Experimental Therapy Poland 27
    4096 Placenta blood Autologous Cerebral Palsy Neurology 2020 Experimental Therapy Poland 2
    4097 Cord Tissue Allogeneic – Unrelated Covid-19 Pulmonology 2020 Experimental Therapy Poland 84
    4098 Cord Tissue Allogeneic – Unrelated Acquired Epileptic Aphasia Neurology 2020 Experimental Therapy Poland 4
    4099 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2020 Experimental Therapy Poland 8
    4100 Cord Tissue Allogeneic – Unrelated Acute Graft Versus Host Disease Hematology 2020 Experimental Therapy Poland 8